Ceribell │ AI-Powered Point-of-Care EEG

Ceribell, Inc., the developer of the first AI-powered point-of-care EEG diagnostic system, is revolutionizing seizure management in acute care. Our mission is to establish the Ceribell System as the standard of care for EEG in the acute care setting and help clinicians save patient lives. Ceribell is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. The Ceribell System received two FDA Breakthrough Device Designations in 2022, and in 2023, the latest generation of Ceribell’s AI algorithm (Clarity?) made it the first and only device to receive 510(k) clearance for diagnosing electrographic status epilepticus. Subsequently, the Clarity algorithm received a New Technology Add-on Payment (NTAP) from the Centers for Medicare and Medicaid Services (CMS).

网站

https://www.ceribell.com

Ceribell │ AI-Powered Point-of-Care EEG的外部链接

所属行业

医疗设备制造业

规模

201-500 人

总部

Sunnyvale，California

类型

私人持股

创立

2014

领域

neurodiagnostics、Brain waves、Electroencephalography (EEG)、Epilepsy、Seizures、Coma、Brain monitor、Point-of-care、Healthcare、Technology、disruptive和Rapid EEG